Company Number: 14031017

Analysis Date: 2025-07-20 17:58 UTC

1. Credit Opinion: DECLINE
   NUTRALYNX LIMITED exhibits negative net current assets and net liabilities in both 2023 and 2024 financial years, indicating poor liquidity and an inability to cover short-term obligations. The company's current liabilities exceed current assets by £3,456 in 2024, worsening from £1,650 in 2023, which signals an increasing strain on working capital. The absence of employees and micro-entity classification imply minimal operational scale and possibly limited revenue generation capacity. Without evidence of positive cash flow or asset support, the company does not currently demonstrate the ability to service debt or sustain credit risk.

2. Financial Strength: Weak
   The balance sheet shows persistent net liabilities with shareholders' funds negative at £3,456 in 2024, deteriorating from £1,650 the prior year. No fixed assets are reported, and current assets are minimal (£944 in 2024), primarily indicating cash or receivables insufficient to meet creditors (£4,400). The financial trajectory is downward, with increasing liabilities and declining equity. This suggests inadequate capitalization and potential solvency concerns, undermining the company’s financial resilience.

3. Cash Flow Assessment: Constrained
   Given the negative working capital position and lack of employees, cash generation capacity appears negligible or negative. The rise in creditors without corresponding asset growth may reflect unpaid obligations or delayed payments. The company may rely on shareholder funding or external support to meet immediate liabilities, indicating liquidity stress. No audit or detailed cash flow statements are available to confirm operating cash flow, further limiting confidence in cash coverage.

4. Monitoring Points:

• Track changes in net current assets and net liabilities for signs of improvement or further deterioration.
• Monitor filings for any injections of capital or restructuring of liabilities.
• Review subsequent financial statements for evidence of revenue growth or cash flow generation.
• Observe any director or shareholder changes that might affect governance or funding.
• Watch for overdue statutory filings or late payments which could indicate worsening financial health.